Tirzepatide as a Novel Therapeutic Option for Patients with Type 2 Diabetes: A Pooled Analysis of SURPASS 1-5 trials
Year: 2022
Type: article
Abstract: Aim: The aim of this study was to evaluate the impact of patients’ characteristics on the efficacy and the safety of subcutaneous tirzepatide once-weekly in patients with uncontrolled type 2 diabetes mellitus (T2DM). Materials and Methods: This post hoc analysis of pooled SURPASS 1-5 randomized controlled trials narratively examined changes from baseline in hemoglobin A1c (HbA1c) and body weight and the proportions of patients who achieved the endpoint composite HbA1c with tirzepatide (5, 10, and 15 mg) across the following subgroups; baseline HbA1c (≥ 7.5% to ≤8.0% [≥48 ≤ 64 mmol/mol], ≥8.0% to ≤8.5% [≥64 ≤68 mmol/mol], and ≥ 8.5% to ≤9.0% [≥68 ≤75 mmol/mol]), baseline diabetes durations (≤ 5 years, 5–10 years, and ≥ 10 years), and age (non-elderly ≤ 60 years and elderly ≥ 60 years). Results: Based on diabetes duration, the mean HbA1c reduced from baseline (≥–1.87 % to ≤–2.24% [≥–20.57 to ≤–24.64 mmol/mol]) for tirzepatide 5 mg ( P = 0.308), –1.89 % to –2.43% (–20.79 to –26.73 mmol/mol) with tirzepatide 10 mg ( P = 0.015) and ≥–2.07 % to≤ –2.58 % (≥–22.77 to ≤–28.38 mmol/mol) with tirzepatide 15 mg ( P = 0.010). Similar HbA1c and body weight reductions were observed across other subgroups (baseline HbA1c and age). Conclusion: Tirzepatide was consistently efficacious and safe in the broad spectrum of patients with T2DM subgroups across the SURPASS 1-5 trials.
Source: Journal of Diabetology
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W4378908091
